A Randomized, Multicentral, Phase III Study of Parallel Groups to Compare the Efficiency and Tolerance of Fulvestrant Administered for Three Years in Combination With Anastrozol for 5 Years Versus Anastrozol for 5 Years as Adjuvant Hormonotherapy in Postmenopausal Women With Early Breast Cancer and + HRs.

Trial Profile

A Randomized, Multicentral, Phase III Study of Parallel Groups to Compare the Efficiency and Tolerance of Fulvestrant Administered for Three Years in Combination With Anastrozol for 5 Years Versus Anastrozol for 5 Years as Adjuvant Hormonotherapy in Postmenopausal Women With Early Breast Cancer and + HRs.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Fulvestrant (Primary) ; Anastrozole
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 According to results presented at the 42nd European Society for Medical Oncology Congress, the financer decided to stop the study support after the inclusion of 872 patients due to the negative results of the FACT trial which were made available in 2010.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
    • 25 Oct 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top